Enliven Therapeutics (ELVN)
Develops small-molecule therapies centered on ELVN-001 for chronic myeloid leukemia.
$46.10
vs last close−2.09 (−4.34%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 108.18% | 79.26M shares | |
|---|---|---|---|
| 222 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 2.95% | 2.16M shares | |
| 8 holders · as of Sep 21, 2026 | |||
| Adds to | 111.13% | ||
73.27M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 111.13%; nothing is left for Other.
13F, as of Jun 30, 2026
222 holders · 79.26M shares · 66 new positions · 155 increased · 49 reduced · 20 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 10.03M | 13.68% | +3.20M | Aug 13, 2026 |
| Orbimed Advisors LLC | 6.78M | 9.25% | −1.18M | Aug 14, 2026 |
| Polar Capital Holdings PLC | 6.43M | 8.78% | +1.36M | Aug 14, 2026 |
| BlackRock, Inc. | 4.36M | 5.95% | +675.0K | Aug 7, 2026 |
| Vestal Point Capital, LP | 4.00M | 5.46% | +750.0K | Aug 14, 2026 |
| Commodore Capital LP | 3.28M | 4.47% | 0 | Aug 14, 2026 |
| Price T Rowe Associates Inc /MD/ | 2.90M | 3.96% | +2.81M | Aug 14, 2026 |
| Vanguard Capital Management LLC | 2.57M | 3.51% | +400.8K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 13.30% | 7.87M | 13G | Nov 5, 2025 |
| Orbimed Advisors LLCincl. Orbimed Capital GP Vii LLC, Orbimed Capital LLC +1 more | 9.50% | 6.77M | 13D | Jun 24, 2026 |
| Polar Capital Holdings Plc | 8.46% | 5.06M | 13G | Jun 22, 2026 |
| Commodore Capital LP | 7.70% | 4.80M | 13G | May 15, 2026 |
| Polar Capital LLPincl. Polar Capital Holdings Plc | 5.69% | 2.69M | Nov 13, 2024 | |
| Vestal Point Capital, LP | 5.40% | 3.25M | 13G | May 15, 2026 |
| BlackRock, Inc. | 5.10% | 2.94M | 13G | Jul 17, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 17, 2026 | Helen Louise Collinsofficer: CHIEF MEDICAL OFFICER | Sale · 3 lots | 5,000 | $50.35 | 25,000 |
| Sep 17, 2026 | Benjamin Hohlofficer: CHIEF FINANCIAL OFFICER | Sale · 3 lots | 6,018 | $50.35 | 38,000 |
| Aug 17, 2026 | Helen Louise Collinsofficer: CHIEF MEDICAL OFFICER | Sale · 2 lots | 5,000 | $58.59 | 25,000 |
| Aug 17, 2026 | Benjamin Hohlofficer: CHIEF FINANCIAL OFFICER | Sale · 2 lots | 6,018 | $58.58 | 40,036 |
| Aug 4, 2026 | Mika K. Derynckdirector | Sale | 158,795 | $60.21 | 0 |
| Jul 17, 2026 | Helen Louise Collinsofficer: CHIEF MEDICAL OFFICER | Sale · 5 lots | 5,000 | $52.67 | 25,000 |
| Jul 17, 2026 | Benjamin Hohlofficer: CHIEF FINANCIAL OFFICER | Sale · 5 lots | 6,018 | $52.64 | 46,054 |
| Jul 6, 2026 | Lori Anne Kunkeldirector | Sale · 2 lots | 10,000 | $50.49 | 41,884 |
| Jun 22, 2026 | Orbimed Advisors LLC10 percent owner | Sale · 4 lots | 860,123 | $45.36 | 219,405 |
| Jun 17, 2026 | Helen Louise Collinsofficer: CHIEF MEDICAL OFFICER | Sale · 3 lots | 5,000 | $43.80 | 25,000 |
House and Senate disclosures
Not reported.